Maoyu Extract Suppresses Non-Small Cell Lung Cancer Progression via PI3K/AKT Signaling Blockade: An Integrated Network Pharmacology and Experimental Validation Study.

Authors

Min Song, Jinlong Tan, Luyi Liu, Yuzhen Zhang, Binbin Wang, Yingying Zhai

Published in

Applied biochemistry and biotechnology. Oct 29, 2026. Epub Oct 29, 2026.

Abstract

Non-small cell lung cancer (NSCLC) is a leading cause of global cancer mortality. Maoyu extract (MY) is a traditional Chinese medicine formulation comprising Ranunculus ternatus Thunb. and Houttuynia cordata Thunb., used traditionally to treat inflammatory lung ailments and nodules. This study aims to systematically investigate the anti-NSCLC efficacy of Maoyu extract and elucidate its underlying molecular mechanisms, specifically focusing on the PI3K/AKT signaling axis. Active compounds and targets were screened using the TCMSP database and validated via molecular docking. Predicted mechanisms were verified in vitro using A549 and NCI-H1299 cell lines and in vivo using a syngeneic Lewis lung carcinoma (LLC) mouse model. Network analysis identified 15 active compounds (including β-sitosterol, kaempferol, and quercetin) and 197 targets. MY significantly inhibited cell proliferation, induced apoptosis, and blocked the PI3K/AKT axis. In the LLC model, MY reduced tumor volume by 56.77%, matching cisplatin's efficacy without inducing significant body weight loss. Maoyu extract exerts potent anti-NSCLC effects by suppressing proliferation and inducing apoptosis through the targeted blockade of the PI3K/AKT signaling axis, providing a scientific basis for its traditional use.

PMID:
42955702
Bibliographic data and abstract were imported from PubMed on 30 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.